Copyright © 2013 Knight Sac Media. All rights reserved.http://www.siliconinvestor.com/subject.aspx?subjectid=53848I was surprised to find that there is no thread for ArQule. Perhaps there was once, and it died. Not unlike the stock price. My curiosity got piqued when I found that BVF had recently acquired an 11% stake. Lately Pfizer has taken one of similar size pursuant to a milestone. Currently, ARQL tra...http://www.siliconinvestor.com/images/Logo380x132.pnghttp://www.siliconinvestor.com/subject.aspx?subjectid=5384838013210tuck>>Daiichi Sankyo Company, Limited (TSE 4568) and ArQule, Inc. (ARQL) today announced that the first patient has been enrolled in the pivotal Phase 3 METIV-HCC (MET-high patients with tivantinib in HCC) trial of tivantinib (ARQ 197). Tivantinib, an investigational selective inhibitor of MET, a receptor tyrosine kina...http://www.siliconinvestor.com/readmsg.aspx?msgid=286993901/31/2013 8:32:07 PMpgo-neil>Shouldn't the burn rate decline with the completion of the trial -- or did you already take that out?< I didn't know what to do for several reasons... The last quarterly conference call [http://finance.yahoo.com/news/arqule-reports-second-quarter-2012-110000732.html had a cash bottom line of $75M and a long term ...http://www.siliconinvestor.com/readmsg.aspx?msgid=2844735310/2/2012 3:29:34 PMmopgcwShouldn't the burn rate decline with the completion of the trial -- or did you already take that out? that is a drag to hear though, hopeful arql would get a hit one of these days.http://www.siliconinvestor.com/readmsg.aspx?msgid=2844695010/2/2012 12:49:12 PMpgo-neilBad news for ARQL's flagship drug, Tiva... l think their burn rate is about $50M per year. They have about $70M in the bank and maybe some cash equivalents. I don't think they [or we] can count on many milestones the remainder of the year, so do they cut staff, sell something else [what?]... or continue spending t...http://www.siliconinvestor.com/readmsg.aspx?msgid=2844639010/2/2012 9:22:00 AMArthur RadleyLetter to Shareholders(4/24/12) LETTER TO STOCKHOLDERS We completed a transformational year for ArQule in 2011 marked by noteworthy progress in the development of tivantinib (ARQ 197), our lead product candidate. Tivantinib is an orally administered, small-molecule inhibitor of the c-Met receptor tyrosine kinase, ...http://www.siliconinvestor.com/readmsg.aspx?msgid=281069724/25/2012 10:34:43 PMscaram(o)ucheHi Doc! I was madly shooting at shares just after the news came out, but then took the remainder of the day off. Sorry for not commenting earlier. Missed those shares, which sort of bewildered at the time...... kept shooting, missing, and canceling through a couple of inept minutes. :-( So, I did nothing..... j...http://www.siliconinvestor.com/readmsg.aspx?msgid=280745424/11/2012 11:16:31 AMArthur RadleyFunny! Yesterday when they announced the deal they mentioned Citi and Leerink as the parties managing the deal. Now today when they have priced the shares they reveal that Lazard, RBC and Oppenheimer are in on the deal. Black helicopter conspiracy----could these guys have been in on the massive sell off yesterday, k...http://www.siliconinvestor.com/readmsg.aspx?msgid=280744364/11/2012 10:47:01 AMtuckPriced at $7.30. How much is timing, announcing this during one of the bigger one day selloffs of the year? Whatever, 'tis bouncing this morning to $7.80. I expect further market weakness and an undercut of the offering price, back to the low $7s. But this remains a long term investment for my Mom's account, not a ...http://www.siliconinvestor.com/readmsg.aspx?msgid=280742874/11/2012 10:08:58 AMArthur RadleyLocation! Location--in buying real estate! Timing! Timing--in buying biotechs. Lucky for me, my entry price for ARQL is lowering than the drop today, but I broke a cardinal rule in that I had told my best friend to buy ARQL if it broke the 52 week high of $8.18----so guess who bought yesterday? (:<)http://www.siliconinvestor.com/readmsg.aspx?msgid=280724134/10/2012 2:37:46 PMtuckNIce of them to wait until the price got back to levels at which they previously financed. Last offering was way back in '07, when there was still some hope for 501, and if memory serves, they expected the cash to last five years. That would have been time enough to get it commercialized had it demonstrated merit. I...http://www.siliconinvestor.com/readmsg.aspx?msgid=280718594/10/2012 12:16:08 PMdr.praveenwhat did you do here rick:-) I wished they waited for 6m... WOBURN, Mass.--(BUSINESS WIRE)-- ArQule, Inc. (NASDAQ: ARQL - News) today announced its intention to offer, subject to market and other conditions, 6 million shares of its common stock in an underwritten public offering. The Company also expects to grant t...http://www.siliconinvestor.com/readmsg.aspx?msgid=280714424/10/2012 10:01:47 AMArthur RadleyOver the past weekend, GE Healthcare(GE) and (DYAX)made an annnouncement about their new join effort.... CHALFONT ST GILES, England & BURLINGTON, Mass.--(BUSINESS WIRE)-- GE Healthcare, a unit of GE (NYSE: GE - News), and Dyax Corp. (NASDAQ: DYAX - News) today announced a licensing agreement for the development and c...http://www.siliconinvestor.com/readmsg.aspx?msgid=280574374/3/2012 11:09:14 AMArthur Radleyonclive.com  Interesting article on the c-Met receptor approach for cancer drugs.http://www.siliconinvestor.com/readmsg.aspx?msgid=280453263/29/2012 11:14:00 AMArthur Radleyschwab.wallst.com  Hummmm! Interesting to see the degree that insiders have been accumulating ARQL. These people have themselves, some nice capital gains, IMO!http://www.siliconinvestor.com/readmsg.aspx?msgid=279066461/25/2012 10:38:57 PMArthur Radleyhttp://www.siliconinvestor.com/readmsg.aspx?msgid=278988741/23/2012 10:54:29 AMArthur RadleyBad timing on my part! I sold 1/4 of my position week before last in my effort to reallocate for the year. I still think ARQL has a future, and this news today gives more validate. At least today's action has given me a green position on the shares I've held for a long time.http://www.siliconinvestor.com/readmsg.aspx?msgid=278855951/17/2012 11:24:29 AMtuck>>ArQule Announces Tivantinib Meets Primary Endpoint, Significantly Extending Time to Progression in Phase 2 Trial in Second-Line Hepatocellular Carcinoma WOBURN, Mass.--(BUSINESS WIRE)-- ArQule, Inc. (NASDAQ: ARQL - News) today announced that treatment with tivantinib as single agent therapy produced a statistic...http://www.siliconinvestor.com/readmsg.aspx?msgid=278854651/17/2012 10:33:52 AMlindalibhttp://www.siliconinvestor.com/readmsg.aspx?msgid=2770195210/14/2011 12:51:04 PMD.LuPresented ysterday at USB Global Life Science Conference. Haven't listened to the online recording yet, so couldn't say if there was any information presented that might explain the rise. On the other hand, the SP has been sinking for a while, maybe to level interesting to some.http://www.siliconinvestor.com/readmsg.aspx?msgid=276491119/20/2011 3:12:27 PMArthur RadleyStock up more than 10% on volume nearly double daily norm----wonder what is behind the move!http://www.siliconinvestor.com/readmsg.aspx?msgid=276490009/20/2011 2:32:42 PM